DEERFIELD -- Baxter International Inc. said it plans to acquire Seprafilm Adhesion Barrier and related assets from Sanofi.
Terms of the acquisition were not announced.
Seprafilm currently has a global commercial presence including sales in the U.S., Japan, China, South Korea and France, among others. Sales of the proposed acquired products are expected to be approximately $100 million in the 12 months. Adhesion prevention products, hemostats and sealants are important tools surgeons use to manage intraoperative bleeding and reduce adhesions
"Seprafilm will be a strong complement to our leading hemostat and sealant portfolio, helping us continue to advance the art of healing with optimized patient care in the operating room," said Wil Boren, general manager of Baxter's Advanced Surgery business.
"While Seprafilm is clinically recognized among surgeons globally, we plan to provide commercial support for the product through our dedicated surgery sales force and pursue opportunities for expansion in certain countries," he added.